Drugs from “The Compounding Shop” May Not Be Sterile: FDA Warns

|

Yet another compounding pharmacy is recalling all of its supposedly sterile products, as the FDA continues to crack down following a deadly fungal meningitis outbreak that killed dozens of people nationwide late last year.  

On May 8, the FDA issued an alert to health care professionals indicating that drugs from The Compounding Shop in St. Petersburg, Florida, may not be sterile, even when they claim sterility. Following the alert, a Compounding Shop drug recall was announced.

The drugs were pulled from the market after problems were discovered during a recent FDA inspection of the company’s facility. The agency reports that there were poor sterile production practices being carried out there.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

“If an injectable drug product that is intended to be sterile is contaminated, it could result in a life-threatening infection in patients,” said the FDA’s director of the Center for Drug Evaluation and Research, Dr. Janet Woodcock, in a press release. “We do not have reports of patient infections. However, due to concerns about a lack of sterility assurance at the facility and out of an abundance of caution, we have advised the firm to remove its sterile products from the market to protect patients.”

The recall is the latest in a string of such actions taken by the FDA following a fungal meningitis outbreak that has sickened more than 700 people and killed more than 50. The outbreak has been traced back to the New England Compounding Center (NECC), a compounding pharmacy in Massachusetts. For years the FDA and state authorities knew there was a problem, according to government records, but did not act out of fear of litigation.

The FDA is currently pushing for expanded powers over all compounding pharmacies, which it says it needs to properly carry out its enforcement duties. A bill was introduced in the U.S. Senate last month that would grant much of that power.

NECC has been shut down and all of its drugs were recalled last fall. The company faces an increasing number of fungal meningitis outbreak lawsuits and has declared bankruptcy. The owners also may face criminal charges.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Image Credit: |



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Parties involved in hair relaxer cancer lawsuits meet with a federal judge tomorrow to update the Court on the status of discovery proceedings ahead of bellwether lawsuits.
A federal judge is expected to decide which scientific experts each side may present during the early Depo-Provera meningioma test trials around the middle of next year.